Table 2.
Studies reporting risk factors for thromboembolism in MPN
| Risk Factors | Cervantes et al.1,2 (included PMF) [6] | Keife et al.2 (included PV, ET, PMF, post-ET-MF, post-PV-MF, MPN-U [19] | Rupoli et al.1 (included ET, early/prefibrotic MF) [8] | Barbui et al.1 (included PMF) [13] | Ellot et al.1 (included fibrotic PMF) [12] | Buxhofer-Ausch et al.1(included prefibrotic MF) [14] |
|---|---|---|---|---|---|---|
| Age >60 | NR | NR | + | + | NR | − |
| JAK2 V617F | NR | NR | NR | + | NR | − |
| Leukocytosis >15 × 103 | NR | NR | NR | − | − | +* |
| Platelets >450 × 109/l | +2 | NR | NR | − | NR | NR |
| History of thrombosis | NR | NR | NR | NR | + | − |
| Splenomegaly (palpable) | NR | + | NR | − | NR | NR |
| Hb>11 g/dl | +2 | NR | NR | − | NR | NR |
| Post PV MF | NR | + | NR | NR | NR | NR |
| Any cardiovascular risk factor | +1 | NR | NR | NR | NR | − |
| Prefibrotic MF | +1 | NR | + | NR | NR | NR |
| Cytoreductive therapy | NR | NR | NR | NR | NR | − |
| Platelets<870 ×109 | NR | NR | NR | NR | NR | + |
+ denotes significant association and − denotes no significant association.
*
Leukocytosis >11.2 × 109/L.
1
denotes multivariate analysis,
2
denotes univariate analysis. NR = not reported